HC Wainwright Expects Reduced Earnings for Rockwell Medical

Rockwell Medical, Inc. (NASDAQ:RMTI) – HC Wainwright dropped their Q1 2025 earnings estimates for Rockwell Medical in a report released on Monday, March 24th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.03) for the quarter, down from their prior estimate of ($0.02). HC Wainwright currently has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is $0.03 per share. HC Wainwright also issued estimates for Rockwell Medical’s Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.10) EPS.

Separately, StockNews.com downgraded shares of Rockwell Medical from a “buy” rating to a “hold” rating in a report on Friday, December 20th.

Rockwell Medical Stock Down 3.2 %

Shares of RMTI stock opened at $1.20 on Wednesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.00 and a current ratio of 2.41. Rockwell Medical has a fifty-two week low of $1.18 and a fifty-two week high of $5.15. The firm has a market capitalization of $40.87 million, a PE ratio of -24.00 and a beta of 1.55. The stock’s 50-day simple moving average is $1.78 and its 200-day simple moving average is $2.56.

Rockwell Medical (NASDAQ:RMTI) last issued its earnings results on Thursday, March 20th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.04). Rockwell Medical had a positive return on equity of 8.55% and a negative net margin of 1.25%. The firm had revenue of $24.67 million during the quarter, compared to analysts’ expectations of $23.65 million.

Institutional Investors Weigh In On Rockwell Medical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RMTI. Marshall Wace LLP lifted its holdings in shares of Rockwell Medical by 17.2% in the 4th quarter. Marshall Wace LLP now owns 596,359 shares of the company’s stock valued at $1,217,000 after buying an additional 87,685 shares during the period. Renaissance Technologies LLC raised its position in Rockwell Medical by 285.8% during the fourth quarter. Renaissance Technologies LLC now owns 442,350 shares of the company’s stock valued at $902,000 after acquiring an additional 327,678 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Rockwell Medical by 4.3% in the fourth quarter. Geode Capital Management LLC now owns 320,416 shares of the company’s stock valued at $654,000 after acquiring an additional 13,122 shares during the period. Jane Street Group LLC purchased a new stake in Rockwell Medical in the 3rd quarter worth approximately $534,000. Finally, Walleye Capital LLC acquired a new stake in shares of Rockwell Medical during the 3rd quarter worth approximately $435,000. 23.31% of the stock is owned by institutional investors and hedge funds.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.